- Home
- DWTX vs SONN Comparison
DWTX vs SONN Comparison
Compare DWTX & SONN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DWTX
- SONN
- Stock Information
- Founded
- DWTX 2012
- SONN N/A
- Country
- DWTX United States
- SONN United States
- Employees
- DWTX N/A
- SONN N/A
- Industry
- DWTX
- SONN Biotechnology: Pharmaceutical Preparations
- Sector
- DWTX
- SONN Health Care
- Exchange
- DWTX NYSE
- SONN Nasdaq
- Market Cap
- DWTX 4.0M
- SONN 3.3M
- IPO Year
- DWTX N/A
- SONN N/A
- Fundamental
- Price
- DWTX $2.46
- SONN $2.96
- Analyst Decision
- DWTX
- SONN Strong Buy
- Analyst Count
- DWTX 0
- SONN 3
- Target Price
- DWTX N/A
- SONN $117.33
- AVG Volume (30 Days)
- DWTX 80.6K
- SONN 1.4M
- Earning Date
- DWTX 11-07-2024
- SONN 12-12-2024
- Dividend Yield
- DWTX N/A
- SONN N/A
- EPS Growth
- DWTX N/A
- SONN N/A
- EPS
- DWTX N/A
- SONN N/A
- Revenue
- DWTX N/A
- SONN $55,881.00
- Revenue This Year
- DWTX N/A
- SONN N/A
- Revenue Next Year
- DWTX N/A
- SONN N/A
- P/E Ratio
- DWTX N/A
- SONN N/A
- Revenue Growth
- DWTX N/A
- SONN N/A
- 52 Week Low
- DWTX $1.62
- SONN $2.50
- 52 Week High
- DWTX $23.50
- SONN $18.72
- Technical
- Relative Strength Index (RSI)
- DWTX N/A
- SONN 27.63
- Support Level
- DWTX N/A
- SONN $2.50
- Resistance Level
- DWTX N/A
- SONN $3.50
- Average True Range (ATR)
- DWTX 0.00
- SONN 0.87
- MACD
- DWTX 0.00
- SONN -0.02
- Stochastic Oscillator
- DWTX 0.00
- SONN 5.19
About DWTX DOGWOOD THERAPEUTICS INC
Dogwood Therapeutics Inc formerly Virios Therapeutics Inc is a development-stage biotechnology company. It is focused advancing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response, such as fibromyalgia (FM) and Long-COVID (LC). Its product candidates includes IMC-1 and IMC-2, IMC-1, is intended to synergistically suppress herpesvirus activation and replication with a more specific activity against the Epstein-Barr virus (herpesvirus HHV-4, IMC-2 is a combination of valacyclovir and celecoxib.
About SONN Sonnet BioTherapeutics Holdings Inc.
Sonnet BioTherapeutics Holdings Inc is a clinical-stage biotechnology company. The company has developed FHAB (Fully Human Albumin Binding) technology which is well suited for drug development across a range of human disease areas, including in oncology, autoimmune, pathogenic, inflammatory, and hematological conditions. The firm's pipeline products include SON-080 (low-dose IL-6), SON-1210 (IL15- FHAB-IL12), SON-1010 (IL12-FHAB), and others.